Exosomes are lipid-bilayer-enclosed extracellular vesicles that contain proteins and nucleic acids. They are secreted by all cells and circulate in the blood. Specific detection and isolation of cancer-cell-derived exosomes in the circulation is currently lacking. Using mass spectrometry analyses, we identify a cell surface proteoglycan, glypican-1 (GPC1), specifically enriched on cancer-cell-derived exosomes. GPC1 1 circulating exosomes (crExos) were monitored and isolated using flow cytometry from the serum of patients and mice with cancer. GPC1
1 crExos were detected in the serum of patients with pancreatic cancer with absolute specificity and sensitivity, distinguishing healthy subjects and patients with a benign pancreatic disease from patients with early-and late-stage pancreatic cancer. Levels of GPC1 1 crExos correlate with tumour burden and the survival of pre-and post-surgical patients. GPC1
1 crExos from patients and from mice with spontaneous pancreatic tumours carry specific KRAS mutations, and reliably detect pancreatic intraepithelial lesions in mice despite negative signals by magnetic resonance imaging. GPC1
1 crExos may serve as a potential non-invasive diagnostic and screening tool to detect early stages of pancreatic cancer to facilitate possible curative surgical therapy.
Exosomes are secreted membrane enclosed vesicles (extracellular vesicles) of 50-150 nm diameter 1 . Formed during the inward budding of late endosomes, they develop into intracellular multivesicular endosomes and contain nucleic acids and proteins [2] [3] [4] [5] [6] . Exosomes are released into the extracellular space and enter the circulation [7] [8] [9] [10] . The biogenesis of exosomes is not clear, therefore the term extracellular vesicles is often used 11 . Exosomes-enriched proteins include members of the tetraspanin family (CD9, CD63 and CD81), members of the endosomal sorting complexes required for transport (TSG101 and Alix) and heat-shock proteins (Hsp60, Hsp70 and Hsp90) 12 . Specific markers that distinguish cancer exosomes from normal exosomes are unknown. Identification and isolation of cancer specific exosomes in body fluids could enable the identification of DNA, RNA and proteins without contamination from non-cancer exosomes, and aid in the treatment and management of cancer.
GPC1 is a specific marker of cancer exosomes
Extracellular vesicles from cancer cells (MDA-MB-231), fibroblasts (HDF and NIH/3T3) and non-tumorigenic cells (MCF10A and E10) were isolated by ultracentrifugation 13, 14 , and called exosomes based on the following observations. NanoSight nanoparticle tracking analysis and transmission electron microscopy (TEM) showed extracellular vesicles of 105 6 5 nm (mean 6 s.d.) and 112 6 4 nm in diameter, respectively 15 (Extended Data Fig. 1a, b) . Immunogold TEM (IG-TEM) showed CD9 (Extended Data Fig. 1c ) and flotillin1 and CD81 by immunoblot 15 (Extended Data Fig. 1d and Extended Data Table 1a ). Proteins were evaluated by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) 16 (Extended Data Table 1a and Supplementary Table 1) . Glypican-1 (GPC1) is a membraneanchored protein that is overexpressed in breast and pancreatic cancer [17] [18] [19] . GPC1 was increased in breast and pancreatic cancer cell lines compared to non-tumorigenic cells (Extended Data Fig. 1e , f and Supplementary Fig. 1 ). Using immunoblot and IG-TEM, GPC1 was detected exclusively in cancer exosomes (Fig. 1, Extended Data Fig. 1g and Supplementary Fig. 1 ; HMLE cells).
We performed FACS analysis of exosomes to detect GPC1 protein (Fig. 1c) . IG-TEM identified cancer exosomes with GPC1, while noncancer exosomes did not exhibit GPC1 (Fig. 1d) . Cancer exosomes from sucrose gradients or ultracentrifugation showed GPC1 (Fig. 1c , e, f, Extended Data Fig. 1h and Supplementary Fig. 1 ).
We implanted MDA-MB-231 cancer cells in the mammary fat pads of nude mice. The mice were bled before cancer cell inoculation, and again when tumours reached an average volume of 300, 550, 1,000 and 1,350 mm 3 , and crExos were assessed for the presence of GPC1 (Extended Data Fig. 2a ). The percentage of GPC1 1 crExos increased proportionally with tumour size and correlated with tumour burden (Extended Data Fig. 2b, c) . We stably expressed green fluorescent protein (GFP)-tagged CD63 in MDA-MB-231 cells. CD63 is an established exosomal marker 14 , and MDA-MB-231-CD63-GFP-derived exosomes were uniformly positive for GFP (Extended Data Fig. 2d ). crExos were also collected from mice with orthotopic MDA-MB-231-CD63-GFP tumours, and a subpopulation of the crExos were GFP 1 (Extended Data Fig. 2e ). GPC1 expression was exclusively detected in the GFP 1 crExo fraction but not in GFP 2 crExos (Extended Data Fig. 2f ).
GPC1
1 circulating exosomes are a cancer biomarker
Next, we isolated crExos from patients with breast cancer (n 5 32), pancreatic ductal adenocarcinoma (PDAC, n 5 190) and healthy donors (n 5 100) (patient data in Extended Data Table 2a ). TEM analysis of crExos isolated from the serum revealed a lipid bilayer and CD9 positivity (Extended Data Fig. 3a, b) . crExos from sucrose gradient purification also showed expression of the exosomes marker flotillin1 (Extended Data Fig. 3c , Supplementary Fig. 1 ) 14, 15 . The relative concentration of crExos was significantly higher in the sera of cancer patients compared to healthy donors (Extended Data Fig. 3d) , and the average size of PDAC crExos was significantly smaller than all other crExos (Extended Data Fig. 3e ). Analyses of sera from healthy donors revealed baseline positivity for GPC1 in crExos, ranging from 0.3 to 4.7% (average of 2.3%; Fig. 2a ). We observed that 75% of patients with breast cancer (24 out of 32) demonstrated GPC1 + crExos levels higher than healthy donors (P , 0.0001; Fig. 2a ). Any specific correlation between the level of GPC1 1 crExos and breast cancer subtypes was not appreciated in this patient cohort (luminal A, luminal B or triple-negative subtypes; Extended Data Fig. 3f ). By contrast, all 190 PDAC patients revealed higher levels of GPC1 1 crExos than in healthy donors (P , 0.0001; Fig. 2a and Extended Data Fig. 8a,  b) . These results indicated a strong correlation between GPC1 1 crExos and cancer, particularly for PDAC.
1 crExos contain oncogenic KRAS
G12D
Exosomes contain DNA and RNA 20 . KRAS is a frequently mutated gene in pancreatic cancer and mutant transcripts have been found in circulation 3, 21, 22 . Primary PDAC tumour samples of 47 PDAC patients were sequenced to assess KRAS status. Of these, 16 contained wild-type KRAS, 14 contained KRAS G12D (which encodes the KRAS glycine-to-aspartic-acid substitution mutant), 11 KRAS G12V , 5 KRAS G12R and 1 KRAS G12V/C mutation (Fig. 2b) . Sufficient amount of corresponding serum was available from 10 patients with KRAS G12D and 5 KRAS G12V mutations. IG-TEM in GPC1 1 and GPC1 2 crExos from the same patient confirmed GPC1 presence (Fig. 2c ). All 15 GPC1
1 crExos with tumour validated KRAS mutation revealed identical mutation by quantitative PCR of exosomal messenger RNA (Fig. 2d) . Wild-type KRAS mRNA was found both in GPC1 1 and GPC1 2 crExos, while mutant KRAS transcript was only detected in the GPC1 1 crExos (Fig. 2d ).
GPC1
1 crExos detect early pancreatic cancer
Analysis of the discovery cohort revealed that the levels of GPC1 1 crExos distinguish patients with histologically validated pancreatic cancer precursor lesions (PCPL, n 5 5; Extended Data Table 2a ) from healthy donors and patients with benign pancreatic disease (BPD, n 5 26; Extended Data Table 2a , b and Fig. 2e) . Specifically, the levels of GPC1 1 crExos in the PCPL group (intraductal papillary mucinous neoplasm (IPMN); n 5 5) were consistently higher than the levels of GPC1 1 crExos in the healthy donor group, as well as in the BPD group (which includes 18 patients with pancreatitis and 8 with cystic adenomas; Fig. 2e ). All patients in PCPL group presented with specific clinical symptoms and exhibited a macroscopic mass using MRI or computed tomography. The BPD group exhibited similar GPC1 1 crExos levels (average 2.1% GPC1 1 crExos) to healthy donors (Fig. 2e) . We compared the specificity and sensitivity of GPC1 1 crExos to levels of carbohydrate antigen 19-9 (CA19-9; also known as sialyl Lewis A ), the clinical standard tumour biomarker for patients with PDAC
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. CA19-9 levels were increased in the serum of patients with PDAC when compared to healthy donors, but CA19-9 levels were also significantly increased in the serum of patients with BPD (P , 0.0001; Extended Data Fig. 3g) . Notably, CA19-9 levels failed to distinguish patients with PCPL from healthy donors (Extended Data Fig. 3g ). When comparing patients with stage I-IV pancreatic cancer to healthy donors and patients with BPD, the receiver operating characteristic (ROC) curves show that GPC1 1 crExos revealed a near perfect classifier with an AUC of 1.0 exhibiting a sensitivity and specificity of 100%, and with a positive and negative predictive value of 100% ( Fig. 2f and Extended Data Fig. 4a-f) . By contrast, CA19-9 was inferior in distinguishing patients with PDAC from healthy donors (P , 0.001; Fig. 2f and Extended Data Fig. 4a-f ). Of note, neither the concentration of exosomes nor their size was a valid parameter to distinguish PDAC patients from controls ( Fig. 2f and Extended Data Fig. 4a-f ). GPC1 1 crExos showed a sensitivity and specificity of 100% in each stage of pancreatic cancer (carcinoma in situ, stage I as well as stages II-IV), supporting its utility as a biomarker for all stages of pancreatic cancer and its potential for early detection of the disease.
An independent patient cohort, composed of 6 patients with histologically validated BPD (chronic pancreatitis), 56 patients with PDAC and 20 healthy donors, was used to validate our findings (Extended Data Table 2a ). GPC1
1 crExos distinguished patients with PDAC from healthy donors and BPD patients (Fig. 2g) . The BPD group exhibited similar GPC1 1 crExos levels to healthy donors (Fig. 2g) . In complete agreement with the discovery cohort, ROC curves indicated that GPC1 1 crExos (from patients with PDAC or BPD and healthy donors) revealed a near perfect classifier with an AUC of 1.0, and sensitivity, specificity, positive and negative predictive values of 100% ( Fig. 2h and Extended Data Fig. 4g ).
GPC1
1 crExos inform pancreatic cancer burden
We next sought to evaluate whether GPC1 1 crExo levels could inform on metastatic disease burden of PDAC patients (Extended Data  Table 2a ). GPC1
1 crExos of PDAC patients with distant metastatic disease showed significantly higher levels of bead-bound GPC1 1 crExos (average 58.5%) than patients with metastatic disease restricted to lymph nodes (average 50.5%) or no metastases (average 39.9%; Extended Data Fig. 5a ). Furthermore, we evaluated GPC1 1 crExos in serum of PDAC patients at pre-and post-surgery stages (post-operative day 7; PDAC n 5 29, PCPL n 5 4 and BPD n 5 4; Fig. 3a ). In total, 28 out of 29 PDAC patients and all PCPL patients with longitudinal blood collections showed a significant decrease in GPC1 1 crExo levels after surgical resection (PDAC: P , 0.0001; PCPL: P , 0.001; Fig. 3b ). By contrast, CA19-9 levels decreased in only 19 out of 29 PDAC patients, and in none of the PCPL patients (PDAC: P 5 0.003; PCPL: P 5 0.81; Extended Data Fig. 5b) . In 4 BPD patients, neither the levels of GPC1
1 crExos nor the levels of CA19-9 showed a difference ( Fig. 3b and Extended Data Fig. 5b ). 
ARTICLE RESEARCH
To determine the prognostic relevance of GPC1 1 crExos in this longitudinal study (Fig. 3a) , patients were dichotomized into two groups. Group 1 was defined by a decrease of GPC1 1 crExos greater or equal to the median decrease in GPC1 1 crExos, and group 2 was defined by a decrease of GPC1 1 crExos that was less than the median decrease of GPC1 1 crExos. Group 1 presented with improved overall (26.2 months) and disease-specific (27.7 months) survival when compared to group 2 (15.5 months for both overall and disease-specific; Fig. 3c, d ). Although a decrease in CA19-9 levels is noted, this decrease did not significantly associate with overall and disease-specific survival (Fig. 3e, f and Extended Data Fig. 5b ). Using a Cox regression model for a multivariate analysis confirmed the decrease in GPC1 1 crExos, as an independent prognostic and predictive marker for disease-specific survival (Extended Data Fig. 5c, d) .
Next, we evaluated whether an ELISA for circulating GPC1 could function with the same specificity and sensitivity as GPC1 1 crExos. Serum samples of the validation cohort (20 healthy donors, 6 BPD and 56 PDAC patients) were analysed for circulating GPC1 levels. While GPC1 levels were significantly higher in patients with PDAC than in patients with BPD and healthy donors, the sensitivity and specificity of the assay was lower when compared to GPC1 1 crExos. The GPC1 ELISA was similar to circulating CA19-9 assay. ROC curves indicated that circulating GPC1 protein shows an AUC of 0.781 a sensitivity of 82.14%, a specificity of 75%, and positive and negative predictor values of 4% and 100%, respectively (Extended Data Fig. 5e , f).
GPC1
1 crExos detect early PanIN lesions
We next evaluated the longitudinal appearance in the serum of GPC1 . The PKT mice consistently progress from pancreatic intraepithelial neoplasia (PanIN) at 4.5 weeks of age and die at 8 weeks of age owing to PDAC 24,25 (Extended Data Fig. 6a ). In a longitudinal study, we bled PKT and littermate control mice repeatedly at 4, 5, 6, 7 and 8 weeks of age (n 5 7 PKT mice and n 5 6 control mice; Fig. 4a ). Then 3 out of 7 PKT mice were euthanized by week 7, along with 4 out of 6 controls, while the remaining 3 PKT mice and 2 controls were euthanized at week 8. At 4 weeks of age, PKT mice showed on average an 8.4% elevation in GPC1 1 crExos, and this increased proportionally with time (and tumour burden) and severity of disease (histopathology), whereas control mice showed an average of 1.2% GPC1 1 crExos and this level remained constant with time ( Fig. 4b) . crExo sizes and concentration did not consistently correlate with disease over time (Extended Data Fig. 6b , c). MRI 26 was performed at the same time points when mice were bled to measure GPC1 1 crExos (Fig. 4c) . When evaluated as a group, GPC1
1 crExo levels appeared before MRI detectable pancreatic masses ( Notably, no increase in GPC1 1 crExo levels was noted in a mouse model of cerulein-induced acute pancreatitis, supporting the idea that the GPC1 1 crExo increase is pancreatic-cancer-specific (Extended Data Fig. 6e ). The ROC curve of GPC1 1 crExos showed an AUC of 1.0 in PKT compared to healthy littermate control mice at all ages evaluated ( Fig. 4e and Extended Data Fig. 6f) .
A cross-sectional study assayed tumour burden and GPC1 1 crExos in PKT mice, as early as 16 and 20 days of age, when they present with 1 exosomes inform pancreatic cancer resection outcome. a, Longitudinal blood collection pre-and postoperatively (day 7). b, Percentage of GPC1 1 crExo beads from patients with BPD (n 5 4), PCPL (n 5 4) or PDAC (n 5 29) (paired two-tailed Student's t-test, **P , 0.01, ****P , 0.0001). Data are mean 6 s.d. c, d, Kaplan-Meier curves (log-rank test) displaying overall (c) and diseasespecific (d) survival of patients with a GPC1 1 crExo drop $ median drop (blue), and with a GPC1 1 crExo drop , median drop (green) after resection. e, f, Kaplan-Meier curves (log-rank test) displaying overall (e) and disease-specific (f) survival of patients with a CA19-9 drop $ median (blue), and a CA19-9 drop , median (green) drop after resection.
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pre-PanIN to early PanIN lesions (Fig. 4f, Extended Data Fig. 7a and Extended Data Table 3 ). GPC1
1 crExos were detected in all PKT mice (PKT: 8.3% average, control: 1.8% average; Fig. 4g and Extended Data Table 1b ). Histological analysis of PKT mice confirmed pre-PanIN lesions in 4 out of 7 PKT mice, and despite no observed histological lesions in 3 out of 7 PKT mice, GPC1
1 crExos predicted future pancreatic cancer emergence (Extended Data Table 1b ). Moreover, we did not observe pancreas-associated masses by MRI in 16-and 20-day-old PKT mice. Both the histopathological score and age of PKT mice correlated with GPC1 1 crExo levels ( Fig. 4h, i) . In 4 out of 7 PKT mice with no observed histological lesions, downstream signals for Kras activation, such as phosphorylated ERK (pERK), were detected in the pancreas tissue ( Fig. 4j and Extended Data Fig. 7a ). We also observed exclusive detection of mutant Kras G12D mRNA in GPC1
1 crExos compared to GPC1 2 crExos (Extended Data Fig. 7b ).
Discussion
Tumour exosomes are enriched in GPC1, and GPC1 1 crExos contain mutant KRAS mRNA. We show that GPC1 1 crExos are a reliable biomarker for detection of early pancreatic cancer. GPC1 1 crExos are a prognostic marker superior to CA19-9. GPC1 1 crExos lead MRI as they can be detected in circulation before MRI-detectable lesions in GEMM of pancreatic cancer.
Routine screening for PDAC using MRI or computed tomography would be prohibitively expensive and associated with a high falsepositive rate 27 . GPC1 1 crExos detect the possibility of pancreatic cancer in 16-day-old mice with unremarkable pancreatic histology and negative MRI. These results suggest the use of GPC1 1 crExos as a detection and monitoring tool for pancreatic cancer, with an emphasis in early detection.
Although KRAS mutations are likely driver mutations for pancreatic cancer and are detected in early PanIN-1 lesions, it is estimated that 15-20 years may lapse before early PanIN lesions become metastatic PDAC [28] [29] [30] . Nonetheless, PDAC currently presents late with nonspecific clinical symptoms, therefore, as many as 80% of patients present with metastasis at diagnosis 31 . Patients with pancreatic cancer exhibit increased serum levels of CA19-9, carcinoembryonic antigen, CA-50, SPan-1, peanut agglutinin, DU-PAN-2, a-fetoprotein, tissue polypeptide antigen and pancreatic oncofetal antigen 32 . While these markers exhibit some use in tracking biopsy-diagnosed disease, they are also increased in patients with BPD. The lack of specific serum biomarkers and retroperitoneal position of the pancreas challenges the early detection of pancreatic cancer 33, 34 . Pancreatico-duodenectomy can be curative if tumours are detected early 35 . Owing to the late diagnosis of pancreatic cancer, only around 15% of patients present with surgically resectable tumours 36 . Studies comparing stage of disease with outcome after surgery suggest that death rates would be reduced if the disease were diagnosed at earlier stages 37 . The isolation of cancer exosomes from patients remains a challenge owing to the lack of specific markers that can distinguish cancer from non-cancer exosomes. Genetic profiling on circulating DNA is cofounded by the fact that the isolated DNA has tumour and non- 1 circulating exosomes predict pancreatic cancer in GEMMs. a, Longitudinal blood collection of control and PKT mice, at 4 (n 5 6 and n 5 7, respectively), 5 (n 5 6 and n 5 7), 6 (n 5 6 and n 5 6), 7 (n 5 6 and n 5 6) and 8 (n 5 2 and n 5 3) weeks of age. b, Percentage of GPC1 1 crExo beads from PKT (red) and control (blue) mice (ANOVA, post-hoc Tukey-Kramer test, ****P , 0.0001; 3 technical replicates). c, MRI with tumour encircled in red. d, Tumour volume and percentage of GPC1 1 crExos in PKT mice at indicated age (ANOVA, post-hoc Tamhane T 2 , *P , 0.05, **P , 0.01, ***P , 0.001 ****P , 0.0001; 3 technical replicates). e, ROC curve analysis of 4-week-old control mice (n 5 6) and mice with acute pancreatitis (n 5 4) versus 4-week-old PKT mice (n 5 7). f, Cross-sectional study; blood collected from 16-or 20-day-old control (n 5 6) and PKT (n 5 7) mice. g, Percentage of GPC1 1 crExo beads from control and PKT (16-20-day-old) mice (paired two-tailed Student's t-test, ****P , 0.0001; 3 technical replicates). h, Graphical representation of correlation between histopathological score and GPC1 1 crExo levels. i, Graphical representation of correlation between age of PKT mice and GPC1 
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tumour origins, thus making mutation detection challenging 38, 39 . We previously demonstrated that the DNA in the circulation is mainly associated with exosomes 6 . Therefore, a marker for cancer exosomes will increase the sensitivity of detection for low frequency mutations in the circulation. As a proof-of-concept, GPC1 1 crExos identified KRAS mutations with 100% correlation with KRAS mutations in the tumour.
Our results provide evidence for GPC1 as a pan-specific marker of cancer exosomes. GPC1 is a proteoglycan that interacts with many proteins and has diverse functions 40 . Many cancer cells overexpress GPC1, with the most abundant increases observed in pancreatic cancer cells lines and tissue [17] [18] [19] . Studies have suggested a role for GPC1 as a positive regulator of cancer progression using orthotopic and GEMMs of PDAC 41, 42 . GPC1 is an attractive candidate for detection and isolation of exosomes in the circulation of patients with cancer for genetic and proteomic analysis of specific alterations. Such opportunity offers the possibility for early detection of pancreatic cancer and help in designing potential curative surgical options.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS
Patient samples and tissue collection. The study was conducted according to the Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) criteria. The studies using human samples were designed as an explorative study. As there was no interventional approach in this study, a priori power calculation was not applicable. Instead, the number of patients included was assessed based on previous studies investigating the diagnostic relevance of circulating biologicals in pancreatic cancer 43 . Serum samples and tissue samples from patients with pancreatic cancer, serum samples only from patients with a benign pancreatic disease and from healthy donors, who had no evidence of acute or chronic or malignant disease and had no surgery within the past 12 months, were received from the department of General, Visceral and Transplantation Surgery from the University of Heidelberg and from the University Hospital of Dresden after approval by the local Institutional Review Board (IRB; Heidelberg: 323/2004, Dresden: EK357112012). The cases were obtained under an IRB-exempt protocol of the MD Anderson Cancer Center (IRB no. PA14-0154). Serum samples from patients with breast cancer were collected at the MD Anderson Cancer Center after approval of the Institutional Review Board (IRB no. LAB10-0690). A written consent for the serum sampling and tumour sampling was obtained pre-operatively from all patients and before serum collection from each healthy donor with disclosure of planned analyses regarding potential prognostic markers. The patients included in this study were all consecutive patients who underwent a surgical procedure at the University Hospital of Heidelberg, Germany, at the University Hospital of Dresden, Germany (pancreatic disease) or at the MD Anderson Cancer Center (breast cancer). All samples were randomly selected from larger cohorts and were analysed in a blinded fashion. Unblinding of clinical parameters and corresponding experimental data was performed only after finishing all experiments. Inclusion criteria of patients were a minimum of 18 years of age, histologically verified pancreatic cancer (pancreatic ductal adenocarcinoma), histologically verified benign pancreatic disease or breast cancer in a resection specimen, and a negative medical history for any other malignant disease. All blood samples were taken before treatment. Inclusion criteria for healthy control donors were a negative medical history for any malignant disease.
On the day of surgery, 10 ml serum separator tubes were used to collect blood samples before surgical incision. The blood samples were then centrifuged at 2,500g for 10 min to extract the serum, and the serum was stored at 280 uC until analysed. Likewise, blood samples were collected on day 7 after surgery for 29 patients with PDAC, 4 patients with chronic pancreatitis and 4 patients with an IPMN. ; p53 R172H/1 (KPC) mice was previously described 32, 33 (total of 13 females and 20 males mice). In the PKT longitudinal cohort, retro-orbital blood collections were performed at 4, 5, 6, 7 and 8 weeks of age. Mice were euthanized at 8 weeks of age or sooner if severe disease symptoms were noted. Histopathological analysis of mouse pancreas specimen was performed following previously defined criteria 4 . Four C57BL/6 adult mice were subjected to repeated cerulean injection to induce acute pancreatitis (five hourly repeated intraperitoneal injections of 50 mg cerulein per kilogram of body weight) and euthanized 24 h after injection the last injection. streptomycin, 20 ng ml 21 EGF, 0.5 mg ml 21 hydrocortisone, 100 ng ml 21 cholera toxin and 10 mg ml 21 insulin. HMEL, MCF-7, MDA-MB-231, HCT-116, SW480, 4T1, NIH/3T3, E10, U87 and B16F10 cells were maintained in DMEM supplemented with 10% (v/v) FBS, 100 U ml 21 penicillin and 100 mg ml 21 streptomycin. Panc-1, MIA Paca2 and T3M4 cells were cultured in RPMI-1640 supplemented with 10% (v/v) FBS, 100 U ml 21 penicillin and 100 mg ml 21 streptomycin. NMuMG cells were grown in DMEM supplemented with 10% (v/v) FBS, 100 U ml 21 penicillin, 100 mg ml 21 streptomycin and 10 mg ml 21 insulin. All cell lines were kept in a humidifying atmosphere at 5% CO 2 at 37 uC. MDA-MB-231-CD63-GFP cells were engineered by transfection with a plasmid encoding a CD63-GFP fusion protein expressed under the control of a CMV promoter (p-CMV6-CD63-GFP from Origene, RG217238). Transfections were performed using Lipofectamine 2000 reagent (Invitrogen). Exosomes isolation from cells. Exosomes were obtained from supernatant of cells as previously described with some modifications 6 . In brief, cells were grown in T225 cm 2 flasks in FBS depleted of exosomes RPMI media until they reached a confluency of 80-90%. Next, the media was collected and centrifuged at 800g for 5 min, followed by a centrifugation step of 2,000g for 10 min to discard cellular debris. Then, the media was filtered using a 0.2-mm pore filter (syringe filter, 6786-1302, GE Healthcare). The collected media was then ultracentrifuged at 100,000g for 2 h at 4 uC. The exosomes pellet was washed with 35 ml PBS, followed by a second step of ultracentrifugation at 100,000g for 2 h at 4 uC. Afterwards, the supernatant was discarded. Exosomes used for RNA extraction were resuspended in 500 ml of Trizol; exosomes used for protein extraction were resuspended in 250 ml of lysis buffer (8 M urea, 2.5% SDS, 5 mg ml 21 leupeptin, 1 mg ml 21 pepstatin and 1 mM phenylmethylsulphonyl fluoride). Exosomes used for flow cytometry analysis (FACS), TEM (see sections below) and immunogold staining were resuspended in 100 ml PBS. Ten microlitres of these exosomes sample were used for NanoSight LM10 (NanoSight Ltd) analysis after dilution 1:100 in PBS. Exosomes isolation from human serum samples. As previously described, 250 ml of cell-free serum samples were thawed on ice 6 . Serum was diluted in 11 ml PBS and filtered through a 0.2-mm pore filter. Afterwards, the samples were ultracentrifuged at 150,000g overnight at 4 uC. Next, the exosomes pellet was washed in 11 ml PBS followed by a second step of ultracentrifugation at 150,000g at 4 uC for 2 h. The supernatant was discarded and pelleted exosomes were resuspended in 500 ml of Trizol for RNA analyses; or in 250 ml of lysis buffer (8 M urea, 2.5% SDS, 5 mg ml 21 leupeptin, 1 mg ml 21 pepstatin and 1 mM phenylmethylsulphonyl fluoride) for protein analyses. Exosomes used for flow cytometry analysis (FACS), TEM (see sections below) and immunogold staining were resuspended in 100 ml PBS. Ten microlitres of this exosomes sample were used for NanoSight LM10 (NanoSight Ltd) analysis after Nano dilution 1:100 in PBS. Immunogold labelling and electron microscopy. Fixed specimens at an optimal concentration were placed onto a 400-mesh carbon/formvar coated grids and allowed to absorb to the formvar for a minimum of 1 min. For immunogold staining the grids were placed into a blocking buffer for a block/permeabilization step for 1 h. Without rinsing, the grids were immediately placed into the primary antibody at the appropriate dilution overnight at 4 uC (1:300 anti-CD9 ab92726, Abcam and anti-GPC1 PIPA528055, Thermo Scientific). As controls, some of the ARTICLE RESEARCH grids were not exposed to the primary antibody. The next day, all the grids were rinsed with PBS then floated on drops of the appropriate secondary antibody attached with 10-nm gold particles (AURION) for 2 h at room temperature. Grids were rinsed with PBS and were placed in 2.5% glutaraldehyde in 0.1 M phosphate buffer for 15 min. After rinsing in PBS and distilled water the grids were allowed to dry and stained for contrast using uranyl acetate. The samples were viewed with a Tecnai Bio Twin transmission electron microscope (FEI) and images were taken with an AMT CCD Camera (Advanced Microscopy Techniques). Sucrose gradient. Sucrose density gradients were performed to purify exosomes. Exosomes were resuspended in 2 ml of HEPES/sucrose stock solution (2.5 M sucrose, 20 mM HEPES/NaOH solution, pH 7.4). The exosomes suspension was overlaid with a linear sucrose gradient (2.0-0.25 M sucrose, 20 mM HEPES/ NaOH, pH 7.4) in a SW41 tube (Beckman). The gradients were ultracentrifuged for 16 h at 210,000g at 4 uC. Gradient fractions of 1 ml were collected from top to bottom and densities of each fractions were evaluated using a refractometer. Next, the exosomes pellets were washed in PBS followed by a second step of ultracentrifugation at 150,000g at 4 uC for 2 h. Exosomes pellets were resuspended in Laemmli buffer and/or PBS for further immunoblot and flow cytometry analysis. Flow cytometry analysis of exosomes-bound beads. Exosomes were attached to 4-mm aldehyde/sulphate latex beads (Invitrogen) by mixing 30 mg exosomes in a 10 ml volume of beads for 15 min at room temperature with continuous rotation. This suspension was diluted to 1 ml with PBS and left for 30 min rotating at room temperature. The reaction was stopped with 100 mM glycine and 2% BSA in PBS and left rotating for 30 min at room temperature. Exosomes-bound beads were washed once in 2% BSA in PBS and centrifuged for 1 min at 14,800g, blocked with 10% BSA with rotation at room temperature for 30 min, washed a second time in 2% BSA and centrifuged for 1 min at 14,800g, and incubated with anti-GPC1 (PIPA528055, Thermo-Scientific, 3 ml of antibody in 20 ml of 2% BSA) during 30 min rotating at 4 uC. Beads were centrifuged for 1 min at 14,800g, the supernatant was discarded and beads were washed in 2% BSA and centrifuged for 1 min at 14,800g. Alexa-488 or Alexa-594-tagged secondary antibodies (Life Technologies, 3 ml of antibody in 20 ml of 2% BSA) were used during 30 min with rotation at 4 uC. Secondary antibody incubation alone was used as control and to gate the beads with GPC1
1 -bound exosomes. The percentage of positive beads was calculated relative to the total number of beads analysed per sample (100,000 events). This percentage was therein referred to as the percentage of beads with GPC1 1 exosomes. UPLC-MS. Exosomes were mixed with 200 ml of methanol spiked with the internal standard tryptophan-d5. After brief vortex mixing, the samples were incubated for 1 h at 220 uC. After centrifugation at 16,000g for 15 min at 4 uC, 190 ml of the supernatants was collected and the solvent removed. The dried extracts were then reconstituted in 15 ml of methanol, of which 10 ml were transferred to microtubes and derivatized. Chromatographic separation and mass spectrometric detection conditions are described in Supplementary Table 2 . The mass range, 50-1,000 m/z, was calibrated with cluster ions of sodium formate. An appropriate test mixture of standard compounds was analysed before and after the entire set of randomized duplicated sample injections, to examine the retention time stability and sensitivity of the LC-MS system throughout the course of the run. Data were processed using the TargetLynx application manager for MassLynx 4.1 software (Waters Corp.). A set of predefined retention time, mass-to-charge ratio pairs (RT-m/z), corresponding to metabolites included in the analysis are fed into the program. Associated extracted ion chromatograms (mass tolerance window 5 0.05 Da) are then peak-detected and noise-reduced in both the LC and MS domains such that only true metabolite related features are processed by the software. A list of chromatographic peak areas is then generated for each sample injection, using the RT-m/z data pairs (retention time tolerance 5 6 s) as identifiers. Normalization factors were calculated for each metabolite by dividing their intensities in each sample by the recorded intensity of the internal standard in that same sample. Visualization of disjoint and overlapping protein data sets was carried out by drawing a VennDiagram of the 5 protein data sets using an R package 45 . CA19-9 human and GPC1 ELISAs. Serum CA19-9 and GPC1 protein levels in patients with pancreatic cancer, pancreatic cancer precursor lesion, or benign pancreatic disease, and in healthy donors were assessed using the Cancer Antigen CA19-9 Human ELISA Kit (Abcam, ab108642) and the GPC1 Human ELISA kit (ABIN840422), according to the manufacturer's directions. Western blot analyses. Cells were lysed in RIPA buffer containing 5 mg ml 21 leupeptin, 1 mg ml 21 pepstatin and 1 mM phenylmethylsulphonyl fluoride. Exosomes were lysed in 8 M urea, 2.5% SDS containing 5 mg ml 21 leupeptin, 1 mg ml 21 pepstatin and 1 mM phenylmethylsulphonyl fluoride. Sample loading was normalized according to Bradford relative protein quantification and proteins separated following an electrophoretic gradient across polyacrylamide gels. Wet electrophoretic transfer was used to transfer the proteins in the gel onto PVDF membranes (ImmobilonP). The protein blot was blocked for 1 h at room temperature with 5% non-fat dry milk in PBS/0,05% Tween and incubated overnight at 4 uC with the following primary antibodies: 1:300 anti-GPC1, PIPA528055 (Thermo-Scientific); 1:300 anti-b-actin A3854 (Sigma-Aldrich); 1:300 anti-CD81 sc-166029 (Santa-Cruz); 1:300 anti-flottilin1 sc-25506 (SantaCruz). Afterwards, horseradish peroxidase (HRP)-conjugated secondary antibodies were incubated for 1 h at room temperature. Washes after antibody incubations were done on an orbital shaker, four times at 10-min intervals, with PBS 0.05% Tween20. Blots were developed with chemiluminescent reagents from Pierce. RNA extraction of cells and exosomes. RNA of cells and exosomes was isolated using Trizol Plus RNA purification kit (Life Technologies, 12183555) according to manufactures protocol. RNA was quantified using a Nanodrop ND-1000 (Thermo Fischer Scientific). qRT-PCR. Quantitative reverse transcriptase PCR (qRT-PCR) was performed on DNase-treated RNA using the SuperScript III Platinum One-Step Quantitative RT-PCR System (11732-088, Invitrogen) according to the manufacturer's directions on a 7300 Sequence Detector System (Applied Biosystems). 150 ng of RNA extracted from 2.5 3 10 8 exosomes was used as qPCR input. Primers for KRAS G12D and KRAS G12V mRNA (both Sigma-Aldrich) were designed as reported previously 46 . In brief, the altered base of the KRAS
G12D
and KRAS G12V mutation was kept at the 39 end of the forward primer. An additional base mutation was included two positions before the KRAS mutation to increase the specificity of the amplification of the mutant KRAS allele. Forward primer sequence for KRAS G12D mRNA: F-59-ACTTGTGGTAGTTGGAGCA GA-39 (italicized bases denote mutations corresponding to the KRAS mutant). Forward primer sequences for KRAS G12V mRNA: F-59-ACTTGTGGTAGTTGG AGCAGT-39. Forward primer sequences for KRAS wild-type mRNA: F-59-AC TTGTGGTAGTTGGAGCTGG-39. Reverse primer for all KRAS mRNAs: R-59-TTGGATCATATTCGTCCACAA-39. GPC1 mRNA primer pairs (PPH06045A) and 18S mRNA primer pairs (QF00530467) were purchased as ready specific primer pairs from Qiagen. Threshold cycle 47 (C t ) the fractional cycle number at which the amount of amplified target reached a fixed threshold, was determined and expression was measured using the 2 2DC t formula, as previously reported 48 . DNA extraction from human primary pancreatic cancer tumours and crExos. Immediately after resection, pancreatic tumour samples were snap-frozen in liquid nitrogen and stored at 280 uC until further processing. A 10-mm reference section of each sample was cut and stained with haematoxylin and eosin by standard methods to evaluate the proportion of tumour tissue and adjacent tumour stroma. Samples with a tumour stroma proportion .30% were excluded into this study. DNA isolation was performed using a commercial DNA Extraction Kit (DNeasy Blood & Tissue Kit, 69506, Qiagen) according to the manufacturer's protocol. The amount of DNA from tumour samples was quantified using a Nanodrop 1000 Spectrophotometer (Thermo Fisher Scientific). PCR and Sanger sequencing. PCR was performed in a 25-ml reaction tube consisting of 10 ml template DNA, 1 mM of each primer, 2.5 mM dNTP, 2.5 ml 103 PCR buffer, 25 mM Mg solution, 0.5 ml H 2 O and 2.5 ml Taq polymerase. Amplification was carried out in a T100 ThermoCycler (Bio-Rad) under the following conditions: 94 uC for 1 min, 2 cycles of 94 uC for 10 s, 67 uC for 30 s, 70 uC for 30 s; 2 cycles of 94 uC for 10 s, 64 uC for 30 s, 70 uC for 30 s; 2 cycles of 94 uC for 10 s, 61 uC for 30 s, 70 uC for 30 s; 35 cycles of 94 uC for 10 s, 59 uC for 30 s, 70 uC for 30 s; endless 4 uC. KRAS amplicon were generated using the following primers: forward 59-AAGGCCTGCTGAAAATGACTG-39, 59-AGAATGGTCC TGCACCAGTAA-39. PCR products were purified using the QIAquick PCR purification kit (Qiagen). Subsequently, sequencing reaction was performed using BigDye terminator kit (v3.1, Life Technologies) according to the manufacturer's instructions. Sequencing products were separated on an ABI 3730 automated sequencer (Life Technologies). KRAS mutation status was evaluated using Finch TV (Geospiza, Inc.). MRI imaging. MRI studies were conducted using a 7T small animal MR system, the Biospec USR70/30 (Bruker Biospin MRI) is based on an actively shielded 7T magnet with a 30-cm bore and cryo-refrigeration. The system is equipped with 6 cm inner-diameter gradients that deliver a maximum gradient field of 950 mT m 21 . A 3.5 cm inner-diameter linear birdcage coil transmits and receives the MR signal. For image acquisition, T2-weighted, respiratory gated, multi-slice imaging will be performed with respiration held to under 25 breaths per minute to minimize motion artefacts in the abdomen. For mice where fat signal might mask the T2 weighted image the fat-suppression pulse module will be used. Acquisition parameters were minimally modified from ref. RESEARCH ARTICLE was chosen to minimize in plane partial volume effects, maintain a FOV sufficient to cover the abdomen, while also providing sufficient throughput for the experiment.
To measure tumour burden, the region of suspected lesions are drawn blinded on each slice after images intensities were normalized. The volume is calculated by addition of delineated region of interest in mm 2 3 1 mm slice distance. Statistical analysis. The GraphPad Prism version 6.0 (GraphPad Software) and MedCalc statistical software version 13.0 (MedCalc Software bvba) were used for all calculations. Unpaired Student's t-test was applied to calculate expression differences of the qPCR results (DC t values). ANOVA tests were performed to calculate differences of multiple serum factors in murine and human serum samples. As a post-hoc test, a Tukey-Kramer test was applied for pairwise comparison of subgroups when the ANOVA test was positive in case of equal variance. Tamhane T 2 test was applied for pairwise comparison of subgroups when the ANOVA test was positive in case of unequal variances. A paired two-tailed Student's t-test was applied to assay differences in the percentage of beads with GPC1 1 crExos and CA19-9 in the longitudinal cohort between pre-operative and postoperative blood samples. ROC curves were used to determine the sensitivity, specificity, positive and negative predictive values and to compare AUCs of serum factors using the Delong method 50 . The cut-off value was determined using the Youden index. Univariate analysis using the log-rank test was conducted to visualize (Kaplan-Meier curves) and assess disease-specific survival (time from diagnosis to cancer-related death or last follow-up) in the longitudinal cohort of patients with pancreatic cancer. A multivariate analysis using the Cox proportional hazards regression model was performed to evaluate the effect of a decrease of the percentage of beads with GPC1 1 crExos in addition to age (continuous variable), AJCC tumour stage, and tumour grade (G) and CA19-9 levels (U ml
21
). Correlation analysis between murine tumour burden and percentage beads with GPC1 1 crExos was performed using the Spearman correlation test. Figures were prepared using GraphPad Prism and MedCalc statistical software version 13.0. All presented P values are two-sided and P , 0.05 was considered to be statistically significant. a, TEM micrograph of serum-derived exosomes from a cancer patient. Top right image shows a digitally zoomed inset. b, TEM micrograph of serumderived exosomes from a cancer patient after immunogold labelling for CD9. Gold particles are depicted as black dots. Top right image shows a digitally zoomed inset. c, Immunoblot of flotillin1 of exosomal protein lysates from serum of cancer patient following exosome purification by a sucrose gradient. The protein content is assayed in each of the density layers listed. d, Exosome concentration by NanoSight analysis showing the number of exosomes per millilitre of serum derived from healthy donors (n 5 100), breast cancer patients (n 5 32) and patients with PDAC (n 5 190) (ANOVA, post-hoc Tamhane T 2 , *P , 0.05, ****P , 0.0001; 3 technical replicates). e, Exosomes size distribution by NanoSight analysis showing the mode size of exosomes in 1 ml of serum derived from healthy donors (n 5 100), breast cancer patients (n 5 32) and patients with PDAC (n 5 190) (ANOVA, post-hoc TukeyKramer test, ***P , 0.001; 3 technical replicates). f, Scatter dot plots depicting the percentage of beads with GPC1 1 -bound exosomes purified from the serum of breast cancer patients. The patients are subdivided into three subtypes: luminal A, luminal B and triple-negative breast cancer. g, Scatter plots depicting the serum CA19-9 concentration (U ml 21 ), evaluated by ELISA, in healthy donors (n 5 100), patients with BPD (n 5 26), PCPL (n 5 5) and PDAC (n 5 190). Discovery cohort, ANOVA, post-hoc Tamhane T 2 , *P , 0.05; ****P , 0.0001; 3 technical replicates. Data are mean 6 s.d.
ARTICLE RESEARCH
RESEARCH ARTICLE
Extended Data Figure 4 | Tumour-stage-specific analysis. a, Table   associated with ROC curve analysis depicted in Fig. 1f . b-f, ROC curve analysis for the percentage of GPC1 1 crExos (red line), CA19-9 serum levels (blue scattered line), exosome concentration (black line) and exosome size (scattered black line) in patients with carcinoma in situ (CIS) or stage I pancreatic cancer (n 5 5) (a), stage IIa pancreatic cancer (n 5 18) (b), stage IIb pancreatic cancer (n 5 117) (c), stage III pancreatic cancer (n 5 11) (d), and stage IV pancreatic cancer (n 5 41) (e), compared to healthy donors (n 5 100) and patients with a benign pancreatic disease (n 5 26), total n 5 126. g, Table  associated with ROC curve analysis depicted in Fig. 1h . CI, confidence interval.
Extended Data Figure 5 | Longitudinal human study. a, Scatter plots of the percentage of beads with GPC1 1 crExos by flow cytometry in patients with pancreatic cancer. Patients are divided based on metastatic disease (nonmetastatic lesions, lymph node metastases and distant metastases) (ANOVA, post-hoc Tukey-Kramer test, *P , 0.05; 3 technical replicates). b, Scatter plots depicting serum CA19-9 levels (U ml 21 ) in patients with BPD (n 5 4), PCPL (n 5 4) and PDAC (n 5 29) on the pre-operative day and post-operative day 7 in patients (paired two-tailed Student's t-test, **P , 0.01; 3 technical replicates). c, d, Multivariate analysis (Cox proportional hazards regression model) of prognostic parameters for overall (c) and disease-specific (d) survival of patients with pancreatic cancer in the longitudinal cohort (n 5 29). e, Scatter plots depicting serum GPC1 (ng ml 21 ) levels by ELISA in patients with BPD (n 5 6), PDAC (n 5 56) and healthy controls (n 5 20) (ANOVA, posthoc Tukey-Kramer test, **** P , 0.0001; 3 technical replicates). f, ROC curve for circulating GPC1 protein (red line) in patients with pancreatic cancer (n 5 56) versus healthy donors (n 5 20) and patients with a benign pancreatic disease (n 5 26), total n 5 6.
Extended Data Figure 6 | PDAC GEMM longitudinal study. a, Schematic diagram depicting the spontaneous development and progression of pancreatic cancer in PKT mice, and haematoxylin and eosin of the pancreas at the indicated time points showing healthy pancreas, and PanIN and PDAC lesions. Scale bars, 100 mm. b, c, Exosome size (b) and concentration (c) assayed by NanoSight analysis from the serum of PKT mice (E: experimental, red) and control mice (C: control, blue) at 4, 5, 6, 7 and 8 weeks of age (ANOVA, posthoc Tukey-Kramer test, *P , 0.05; 3 technical replicates). d, Graph depicting the time-wise progression of tumour volume measured by MRI and the percentage of GPC1 1 -bound crExo beads in individual PKT mice (blue: tumour volume, red: percentage of GPC1 1 crExos). e, Percentage of GPC1 1 crExo beads from control mice (n 5 3) and mice with cerulein-induced acute pancreatitis (n 5 4) (two-tailed Student's t-test, ns: not significant; 3 technical replicates). f, Results from ROC curves for the percentage of GPC1 1 -bound crExo beads, exosome concentration and size in 4-, 5-, 6-and 7-week-old PKT mice (n 5 7) versus control (including age-matched littermate healthy control (n 5 6) and mice with induced acute pancreatitis (n 5 4), n 5 10)). Data are mean 6 s.d. RESEARCH ARTICLE
